What Causes Anemia in a Woman? A Comprehensive Scientific Exploration of the Biological, Nutritional, Hormonal, Genetic, and Medical Factors Behind One of the World’s Most Common Health Disorders (2026)

Introduction

Imagine feeling exhausted after a full night’s sleep, struggling to concentrate during routine tasks, or becoming breathless after climbing a single flight of stairs. Many women attribute these symptoms to stress, lack of sleep, or the demands of modern life. Yet, for hundreds of millions worldwide, these seemingly ordinary experiences are caused by a hidden but highly treatable medical condition: anemia. Understanding “what causes anemia in a woman?” is essential because the condition often develops silently, and its underlying causes extend far beyond simple iron deficiency.

Anemia is one of the most prevalent health disorders globally. According to the World Health Organization (WHO), an estimated 29.9% of women aged 15–49 years are affected by anemia, representing more than 500 million women worldwide. The burden is even greater during pregnancy, where approximately 36.5% of pregnant women are estimated to be anemic. These figures underscore not only a major clinical challenge but also a significant public health concern that affects maternal health, child development, educational attainment, workplace productivity, and national economies.

Despite its widespread occurrence, anemia is often misunderstood. It is commonly equated with iron deficiency, yet iron deficiency accounts for only a portion of all cases. Anemia is not a disease itself, but rather a clinical sign indicating that the body is unable to produce enough healthy red blood cells, maintain sufficient hemoglobin, or compensate for blood loss or increased red blood cell destruction. The underlying causes range from nutritional deficiencies and menstrual blood loss to chronic inflammatory diseases, inherited genetic disorders, kidney disease, gastrointestinal conditions, and certain cancers.

Scientific understanding of anemia has advanced dramatically over the past two decades. The discovery of hepcidin, a hormone that regulates iron metabolism, fundamentally changed how clinicians view iron deficiency and anemia of chronic disease. Researchers now recognize that inflammation can prevent the body from using stored iron, meaning that anemia can occur even when total iron stores appear adequate. At the same time, advances in molecular genetics, laboratory diagnostics, and artificial intelligence are reshaping how anemia is diagnosed and managed.

This article explores the science behind anemia in women, examining the biological mechanisms governing red blood cell production, the unique physiological factors that increase women’s susceptibility, and the latest evidence guiding diagnosis, prevention, treatment, nutrition, and long-term management. It also examines the broader public health impact of anemia, highlights emerging scientific advances, and distinguishes established scientific consensus from developing areas of research, providing a comprehensive, evidence-based understanding of one of the world’s most common—and often overlooked—medical conditions.

Key Statistics at a Glance

Anemia in Women: Key Statistics

• Approximately 30% of women aged 15–49 years worldwide are affected by anemia, according to the World Health Organization (WHO), making it one of the most common health disorders affecting women globally.
• Iron deficiency is the leading cause of anemia worldwide and is estimated to account for at least half of the global anemia burden. However, anemia may also result from chronic inflammatory diseases, vitamin B12 and folate deficiencies, inherited blood disorders, chronic kidney disease, gastrointestinal disorders, and acute or chronic blood loss.
• Pregnancy increases maternal iron requirements by approximately 1,000 mg over the course of gestation to support fetal growth, placental development, expansion of maternal red blood cell mass, and blood loss associated with childbirth.
• Heavy menstrual bleeding (HMB) is one of the leading causes of iron-deficiency anemia in women of reproductive age. Chronic excessive menstrual blood loss can gradually deplete iron stores, making early recognition and appropriate treatment essential to prevent iron-deficiency anemia.

Why It Matters: Anemia is far more than a laboratory finding or a low hemoglobin level. It can impair physical endurance, cognitive function, workplace and academic performance, pregnancy outcomes, and overall quality of life. When left untreated, moderate to severe or chronic anemia may increase cardiovascular strain, contribute to adverse maternal and fetal outcomes, reduce productivity, and diminish overall well-being. Fortunately, many forms of anemia are preventable or highly treatable when the underlying cause is identified early and managed appropriately through evidence-based medical care.

The Global Burden of Anemia

Anemia is far more than an individual health problem. The World Health Organization (WHO) recognizes anemia as a major global public health concern and a significant contributor to disability worldwide, particularly among women and children.

Global Prevalence

According to the WHO Global Anaemia Estimates (2025 edition):

The burden of anemia is not equally distributed. It is substantially more common in low- and lower-middle-income countries, where nutritional deficiencies, infectious diseases, limited access to healthcare, poor sanitation, and maternal health disparities often coexist. However, anemia remains an important health concern in high-income countries as well, particularly among women with heavy menstrual bleeding, chronic illnesses, gastrointestinal disorders that impair nutrient absorption, or restrictive diets.

Why Women Are More Vulnerable

Across the lifespan, women experience several physiological events that increase their susceptibility to anemia:

• Menstruation, which results in regular blood and iron loss.
• Pregnancy, during which iron requirements increase substantially to support fetal growth and the expansion of maternal blood volume.
• Childbirth, which may involve significant blood loss.
• Breastfeeding, which increases maternal nutritional requirements, particularly when iron stores are already depleted.
• Perimenopause, when irregular or prolonged menstrual bleeding may occur.
• Gynecological conditions, such as uterine fibroids, adenomyosis, and endometriosis, may cause chronic or excessive menstrual blood loss.

These biological factors interact with nutritional status, socioeconomic conditions, access to healthcare, and underlying medical conditions, creating a multifactorial risk profile that makes women particularly vulnerable to anemia throughout their reproductive years.

What Is Anemia?

Anemia is a condition in which the number of red blood cells or the hemoglobin concentration in the blood is lower than normal, resulting in a reduced oxygen-carrying capacity of the blood.

Hemoglobin is an iron-containing protein found inside red blood cells (erythrocytes). It binds oxygen in the lungs and transports it to tissues throughout the body while carrying carbon dioxide back to the lungs for exhalation.

Because oxygen is essential for cellular respiration—the process by which cells produce adenosine triphosphate (ATP), the body’s primary energy source—even modest reductions in hemoglobin can impair tissue oxygen delivery and normal physiological function.

Symptoms According to Severity

The clinical manifestations of anemia depend not only on the hemoglobin concentration but also on how rapidly the anemia develops, its underlying cause, the patient’s age, and the presence of cardiovascular or respiratory disease. Individuals with slowly progressive anemia often develop physiological adaptations and may remain relatively asymptomatic despite markedly reduced hemoglobin levels, whereas acute blood loss can cause severe symptoms even with comparatively modest reductions.

Mild Anemia

In the early stages, symptoms may be subtle or absent. Common manifestations include:

• Mild fatigue
• Reduced physical endurance
• Difficulty concentrating
• Occasional dizziness when standing
• Mild headaches
• Decreased work or academic performance

Many women mistakenly attribute these symptoms to stress, inadequate sleep, or a busy lifestyle, delaying diagnosis.

Moderate Anemia

As tissue oxygen delivery becomes increasingly impaired, symptoms become more noticeable:

• Persistent fatigue despite adequate rest
• Shortness of breath during ordinary physical activity
• Palpitations or awareness of the heartbeat
• Pale skin and mucous membranes
• Frequent headaches
• Cold hands and feet
• Reduced exercise tolerance
• Light-headedness

Iron deficiency may also produce characteristic features such as:

• Brittle nails
• Hair loss
• Glossitis (inflamed tongue)
• Angular cheilitis
• Restless legs syndrome
• Pica (craving for non-food substances such as ice, clay, or starch)

Severe Anemia

When hemoglobin falls substantially, tissue oxygen delivery becomes critically compromised, potentially leading to:

• Shortness of breath at rest
• Chest pain
• Rapid heartbeat (tachycardia)
• Fainting (syncope)
• Confusion or altered mental status
• Marked weakness that limits routine activities
• Heart failure in susceptible individuals

Severe anemia accompanied by cardiovascular instability or ongoing blood loss constitutes a medical emergency and requires urgent medical evaluation.

WHO Classification of Anemia

The World Health Organization (WHO) defines anemia using hemoglobin (Hb) concentration thresholds that vary according to age, sex, and physiological status. Hemoglobin values should also be interpreted after appropriate adjustment for altitude and smoking status, where applicable.

WHO Hemoglobin Thresholds for Diagnosis

Severity of Anemia in Non-pregnant Women

Severity of Anemia During Pregnancy

First and Third Trimester

Second Trimester

These hemoglobin thresholds provide a standardized framework for diagnosing and classifying anemia. However, clinicians should always interpret hemoglobin values alongside the patient’s symptoms, medical history, physical examination, underlying cause of anemia, and relevant laboratory findings. Clinical judgment remains essential, particularly in patients with chronic disease, acute blood loss, or conditions that affect hemoglobin measurement.

How Red Blood Cells Are Made

The production of red blood cells, known as erythropoiesis, is one of the body’s most remarkable examples of continuous cellular renewal.

Approximately 2–3 million red blood cells are produced every second, ensuring that oxygen delivery keeps pace with the body’s metabolic demands.

Step 1: Hematopoietic Stem Cells

All blood cells originate from hematopoietic stem cells (HSCs) located primarily within the bone marrow.

Hematopoietic stem cells first differentiate into myeloid and lymphoid progenitor cells.

• Myeloid progenitors give rise to:
  • Red blood cells
  • Platelets
  • Several types of white blood cells (such as neutrophils, eosinophils, basophils, and monocytes)
• Lymphoid progenitors give rise to:
  • Lymphocytes (B cells, T cells, and natural killer cells)

The commitment of stem cells to the red blood cell lineage is regulated by a combination of growth factors, transcription factors (such as GATA-1 and KLF1), and hormones, ensuring the production of healthy red blood cells.

Step 2: Erythropoietin—The Oxygen Sensor

Specialized oxygen-sensing cells in the kidneys continuously monitor the body’s oxygen supply.

When oxygen levels decline, these cells activate the hypoxia-inducible factor (HIF) pathway, which increases the production of erythropoietin (EPO).

EPO travels through the bloodstream to the bone marrow, where it stimulates immature red blood cell precursors to proliferate, differentiate, and mature.

This forms a negative feedback loop: as oxygen delivery improves, erythropoietin production decreases, helping maintain a stable red blood cell count.

Patients with chronic kidney disease (CKD) often develop anemia because damaged kidneys produce insufficient erythropoietin.

Step 3: Building Hemoglobin

Producing functional hemoglobin requires several essential nutrients:

A deficiency in any of these nutrients can impair erythropoiesis and contribute to anemia.

The Life Cycle of a Red Blood Cell

A mature red blood cell circulates for approximately 120 days.

Its life cycle consists of five stages:

1. Production in the bone marrow.
2. Circulation, where red blood cells transport oxygen from the lungs to tissues and return carbon dioxide to the lungs.
3. Senescence, as aging cells gradually lose flexibility and become less efficient.
4. Removal by macrophages, primarily in the spleen, as well as in the liver and bone marrow.
5. Iron Recycling, in which iron recovered from old red blood cells is transported back to the bone marrow and reused to produce new hemoglobin.

Remarkably, approximately 90–95% of the iron needed for new red blood cell production comes from recycling iron from aging red blood cells. Only about 1–2 mg of iron is normally absorbed from the diet each day to replace the small amount of iron lost through normal physiological processes. This highly efficient recycling system minimizes dependence on daily dietary iron intake.

Iron Metabolism: More Than Just Diet

Iron is indispensable for life, yet it is also potentially toxic if present in excess. Consequently, the body regulates iron with extraordinary precision.

Iron Absorption

Dietary iron is absorbed primarily in the duodenum, the first segment of the small intestine.

Iron occurs in two forms:

• Heme iron, found in meat, poultry, and fish, is readily absorbed.
• Non-heme iron, found in plant-based foods, is less efficiently absorbed and is more influenced by dietary enhancers (such as vitamin C) and inhibitors (such as phytates and tannins).

Because humans lack a regulated pathway for excreting excess iron, absorption—not elimination—is the principal mechanism controlling iron balance.

Hepcidin: The Master Regulator of Iron Homeostasis

One of the most important discoveries in modern hematology is hepcidin, a peptide hormone produced by the liver.

Hepcidin regulates the activity of ferroportin, the only known cellular iron exporter.

When hepcidin levels are low, ferroportin remains active, allowing iron to leave intestinal cells and storage sites, increasing circulating iron available for hemoglobin synthesis.

When hepcidin levels are high, ferroportin is degraded, preventing iron export. As a result:

• Intestinal iron absorption decreases.
• Iron becomes trapped within macrophages and liver cells.
• Less iron reaches the bone marrow.

This mechanism explains why chronic inflammatory diseases can produce anemia despite apparently normal or elevated iron stores.

Erythroferrone: Balancing Iron Supply

A more recently discovered hormone, erythroferrone, is produced by developing red blood cell precursors in the bone marrow.

When erythropoiesis accelerates—such as after blood loss—erythroferrone suppresses hepcidin production. This allows more iron to enter the bloodstream, ensuring that the bone marrow receives sufficient iron to produce additional red blood cells.

The interplay between erythropoietin, erythroferrone, hepcidin, and ferroportin forms a finely tuned regulatory network that maintains iron homeostasis under both normal and pathological conditions.

Anemia Is Not a Single Disease

One of the most common misconceptions about anemia is that it is a single disease caused only by iron deficiency. In reality, anemia is a clinical syndrome rather than a disease itself. It develops when the blood’s ability to transport oxygen is reduced because there are too few healthy red blood cells, insufficient hemoglobin, or both. Consequently, anemia represents a sign of an underlying medical condition rather than a diagnosis on its own.

Although dozens of disorders can lead to anemia, physicians generally classify the underlying mechanisms into three broad categories: blood loss, reduced red blood cell production, and increased red blood cell destruction (hemolysis). Understanding these mechanisms is essential because successful treatment depends on identifying and correcting the underlying cause rather than simply increasing hemoglobin levels.

Women are particularly susceptible to anemia because normal physiological processes such as menstruation, pregnancy, and childbirth can increase iron requirements or lead to chronic blood loss. In addition, nutritional deficiencies, chronic illnesses, inherited blood disorders, and certain medications may contribute to one or more of these mechanisms.

Blood Loss

Blood loss is one of the most common causes of anemia in women because red blood cells are lost from the circulation faster than the bone marrow can replace them. Acute blood loss may occur suddenly, such as after trauma or major surgery, whereas chronic blood loss develops gradually over weeks, months, or even years. Chronic bleeding often goes unnoticed until iron stores become depleted and symptoms of anemia appear.

Among women of reproductive age, heavy menstrual bleeding is a leading cause of chronic blood loss. Excessive menstrual bleeding can progressively reduce the body’s iron reserves, eventually impairing hemoglobin production and causing iron-deficiency anemia. Gynecological conditions such as uterine fibroids, adenomyosis, endometrial polyps, endometriosis, and inherited bleeding disorders can all contribute to excessive menstrual blood loss.

Blood loss may also originate outside the reproductive system. Gastrointestinal disorders—including peptic ulcers, gastritis, inflammatory bowel disease, colon polyps, colorectal cancer, and gastric cancer—can cause chronic microscopic bleeding that remains undetected for long periods. For this reason, unexplained iron-deficiency anemia in postmenopausal women requires careful evaluation to identify possible gastrointestinal sources of bleeding.

Reduced Red Blood Cell Production

Anemia also develops when the bone marrow cannot produce enough healthy red blood cells to meet the body’s oxygen demands. Normal red blood cell production, or erythropoiesis, requires healthy bone marrow, adequate erythropoietin production by the kidneys, and sufficient nutrients such as iron, vitamin B12, folate, vitamin B6, copper, and protein.

Iron deficiency is the most common cause of impaired red blood cell production worldwide. However, deficiencies of vitamin B12 or folate can also interfere with DNA synthesis, preventing immature red blood cells from developing normally. In these situations, the bone marrow produces fewer functional red blood cells, reducing the blood’s oxygen-carrying capacity.

Reduced production may also occur in chronic medical conditions. Chronic kidney disease decreases erythropoietin production, limiting stimulation of the bone marrow. Chronic inflammatory diseases increase hepcidin production, reducing iron availability despite normal or elevated iron stores. Bone marrow disorders, certain cancers, chemotherapy, and some medications may directly suppress red blood cell production as well.

Because these conditions affect different biological pathways, treatment must address the underlying disorder rather than relying solely on iron supplementation.

Increased Red Blood Cell Destruction (Hemolysis)

The third major mechanism is hemolysis, in which red blood cells are destroyed faster than the bone marrow can replace them. Under normal conditions, red blood cells circulate for approximately 120 days before macrophages remove them in the spleen and liver. During hemolytic anemia, this lifespan is significantly shortened, leading to a persistent reduction in circulating red blood cells.

Hemolysis may result from inherited disorders or acquired conditions. Inherited diseases such as sickle cell disease, thalassemia, and hereditary spherocytosis alter the structure or function of red blood cells, making them more fragile or less flexible and increasing their premature destruction. Acquired causes include autoimmune disorders, certain infections, medications, and mechanical damage to red blood cells.

As red blood cells break down, patients may develop features such as jaundice, dark urine, splenomegaly, elevated bilirubin, and increased lactate dehydrogenase levels. The bone marrow often attempts to compensate by increasing red blood cell production, but if destruction continues to outpace production, anemia develops.

Recognizing hemolysis is important because treatment differs substantially from that used for iron-deficiency anemia. Simply replacing iron is ineffective unless iron deficiency is also present; instead, management focuses on identifying and treating the underlying cause of excessive red blood cell destruction.

Anemia Across the Female Life Course

The causes of anemia evolve throughout a woman’s lifetime. Age, hormonal changes, reproductive events, diet, and chronic medical conditions all influence risk.

Adolescence: A Period of Rapid Growth and Rising Iron Demand

Adolescence marks one of the most vulnerable periods for iron deficiency. During puberty, the body undergoes rapid expansion in height, muscle mass, blood volume, and organ development. These changes substantially increase the need for iron.

For girls, the onset of menstruation introduces a new and recurring source of iron loss. If dietary intake does not keep pace with increased requirements, iron stores gradually decline.

Additional factors that increase risk during adolescence include:

• Diets low in iron-rich foods
• Restrictive eating patterns or eating disorders
• Vegetarian or vegan diets without careful planning
• Intense athletic training
• Frequent blood donation in older adolescents

Several studies have shown that even before anemia develops, iron deficiency can impair attention, learning, memory, and physical performance. This highlights the importance of recognizing iron deficiency without anemia, an increasingly recognized clinical entity.

Reproductive Years: The Impact of Menstruation

Throughout the reproductive years, menstruation becomes the dominant physiological determinant of iron balance.

During a typical menstrual cycle, blood loss averages 30–40 milliliters, corresponding to approximately 15–20 milligrams of iron. Most healthy women compensate for these losses through efficient iron recycling and dietary absorption.

However, not all menstrual cycles are typical.

Women with heavy menstrual bleeding (HMB) may lose more than 80 milliliters of blood per cycle. However, newer clinical guidelines emphasize the impact on quality of life rather than a strict volume threshold. Excessive menstrual blood loss can gradually deplete iron stores over months or years, eventually leading to iron-deficiency anemia.

Symptoms of heavy menstrual bleeding include:

• Needing to change pads or tampons every one to two hours
• Passing large blood clots
• Bleeding lasting more than seven days
• Requiring double protection
• Frequent nighttime changes
• Menstrual bleeding that interferes with work, school, or daily activities

Because blood loss occurs gradually, many women adapt to worsening fatigue and reduced exercise tolerance without recognizing anemia until symptoms become severe.

Pregnancy: A Physiological Stress Test

Pregnancy represents one of the greatest challenges to maternal iron metabolism.

To support fetal growth, placental development, and expansion of maternal blood volume, iron requirements increase dramatically. Approximately 1,000 milligrams of additional iron are required over the course of pregnancy.

This requirement is distributed among:

• Expansion of maternal red blood cell mass
• Development of the fetus
• Formation of the placenta
• Blood loss during childbirth

An important physiological adaptation occurs during pregnancy: plasma volume expands more rapidly than red blood cell mass, producing physiological dilutional anemia. This normal change should not be confused with pathological iron-deficiency anemia.

Clinicians therefore interpret hemoglobin values during pregnancy using trimester-specific expectations and additional laboratory tests, particularly serum ferritin.

Postpartum Recovery

Following childbirth, many women continue to experience iron deficiency due to:

• Blood loss during delivery
• Cesarean section
• Multiple pregnancies in close succession
• Pre-existing iron deficiency during pregnancy
• Increased nutritional demands while breastfeeding

Postpartum anemia has been associated with fatigue, impaired physical recovery, reduced quality of life, and postpartum depression in some studies. While these associations are well documented, anemia is only one of many factors influencing postpartum mental health, and causation is likely multifactorial.

Early recognition and treatment can substantially improve maternal recovery.

Perimenopause and Menopause

The years leading to menopause often involve irregular hormonal fluctuations that can produce unusually heavy or prolonged menstrual bleeding.

Common contributing conditions include:

• Uterine fibroids
• Adenomyosis
• Endometrial polyps
• Hormonal imbalance

After menopause, menstrual blood loss should cease. Consequently, new-onset iron-deficiency anemia in postmenopausal women warrants careful evaluation, particularly for gastrointestinal blood loss.

Potential causes include:

• Peptic ulcers
• Colon polyps
• Colorectal cancer
• Gastric cancer
• Inflammatory bowel disease

Because gastrointestinal malignancies become more common with age, unexplained iron-deficiency anemia in postmenopausal women should never be attributed to diet alone without appropriate medical investigation.

Nutritional Causes of Anemia

Although iron deficiency is the most common nutritional cause, several nutrients are essential for healthy red blood cell production.

Iron Deficiency: The Leading Cause Worldwide

Iron deficiency remains the most common cause of anemia globally.

The body contains approximately 2–3 grams of iron, distributed among:

• Hemoglobin (~65–70%)
• Ferritin and hemosiderin storage proteins
• Myoglobin in skeletal muscle
• Various enzymes involved in cellular metabolism

Unlike many nutrients, iron is not actively excreted. Instead, the body conserves iron through efficient recycling of aging red blood cells. Daily dietary absorption replaces only the small amount lost through skin, intestinal cells, and minor bleeding.

Iron deficiency develops gradually through three overlapping stages:

Stage 1: Iron Store Depletion

Iron reserves within ferritin begin to decline, but hemoglobin remains normal.

Symptoms are usually absent.

Stage 2: Iron-Restricted Erythropoiesis

Iron stores become insufficient to fully support red blood cell production.

Some individuals begin experiencing:

• Fatigue
• Reduced concentration
• Lower exercise tolerance

Hemoglobin may remain within the normal range.

Stage 3: Iron-Deficiency Anemia

Eventually, hemoglobin synthesis becomes impaired.

Red blood cells become:

• Smaller (microcytic)
• Paler (hypochromic)

Clinical symptoms become increasingly apparent as oxygen delivery declines.

Vitamin B12 Deficiency

Vitamin B12 is essential for DNA synthesis within rapidly dividing cells.

Without adequate B12, developing red blood cells cannot mature normally. Instead, they become unusually large and fragile—a condition known as megaloblastic anemia.

Common causes include:

• Pernicious anemia (an autoimmune disorder affecting intrinsic factor production)
• Long-term vegan diets without supplementation
• Gastric bypass surgery
• Chronic gastritis
• Crohn’s disease affecting the terminal ileum
• Certain medications, including prolonged metformin or proton pump inhibitor use in susceptible individuals

Unlike iron deficiency, vitamin B12 deficiency may also cause neurological complications, including numbness, tingling, balance problems, and memory impairment. Some neurological damage can become irreversible if treatment is delayed.

Folate (Vitamin B9) Deficiency

Folate plays a central role in DNA replication and cell division.

Requirements increase substantially during:

• Pregnancy
• Rapid growth
• Chronic hemolytic disorders

Poor intake, alcohol misuse, malabsorption syndromes, and certain medications can contribute to deficiency.

Because folate supplementation can partially correct anemia while allowing neurological damage from vitamin B12 deficiency to progress, clinicians generally evaluate both nutrients when megaloblastic anemia is suspected.

Less Common Nutritional Deficiencies

Although uncommon in developed healthcare settings, deficiencies of other nutrients may also impair erythropoiesis.

These include:

• Copper deficiency, which interferes with iron transport and utilization.
• Vitamin A deficiency, which influences iron metabolism and immune function.
• Vitamin B6 deficiency, required for heme synthesis.
• Severe protein-energy malnutrition, limiting globin protein production.

These conditions are relatively rare but should be considered in patients with complex nutritional disorders or malabsorption syndromes.

Gynecological Causes of Blood Loss

While nutritional deficiencies often receive the greatest attention, chronic gynecological blood loss remains one of the leading causes of iron deficiency and iron-deficiency anemia in women of reproductive age.

Common underlying conditions include:

Recognizing these conditions is essential because treating the underlying cause of abnormal uterine bleeding—along with correcting iron deficiency—provides the most effective long-term management and helps prevent recurrent anemia.

Chronic Diseases: When Iron Is Present but Unavailable

For decades, physicians believed that most anemia resulted simply from insufficient dietary iron or blood loss. Research over the past two decades has fundamentally changed this understanding.

Many women with chronic illnesses have adequate total body iron, yet the iron cannot be efficiently used to produce hemoglobin. This condition, known as anemia of chronic disease or anemia of inflammation, is the second most common form of anemia worldwide after iron-deficiency anemia.

Unlike iron-deficiency anemia, the problem is not a lack of iron—it is a failure of iron mobilization.

The Biology of Anemia of Inflammation

When the immune system detects infection, injury, autoimmune disease, or cancer, it releases signaling proteins called cytokines. One of the most important is interleukin-6 (IL-6).

IL-6 stimulates the liver to produce hepcidin, the hormone introduced in Part 1.

Elevated hepcidin produces several coordinated effects:

• It reduces iron absorption from the intestine.
• It blocks iron release from macrophages, which recycle aging red blood cells.
• It traps iron inside liver storage cells.
• It limits the amount of circulating iron available to the bone marrow.

This response is thought to have evolved as a defense mechanism because many bacteria require iron to multiply. By restricting circulating iron, the body may reduce microbial growth during infection. However, when inflammation becomes chronic, this protective strategy also limits iron availability for red blood cell production.

The result is functional iron deficiency: iron is present but biologically inaccessible.

Diseases Commonly Associated with Anemia of Inflammation

Women living with the following conditions have an increased risk:

• Rheumatoid arthritis
• Systemic lupus erythematosus (SLE)
• Inflammatory bowel disease
• Chronic liver disease
• Tuberculosis
• HIV infection
• Chronic heart failure
• Obesity-associated chronic inflammation
• Many cancers

The severity of anemia often parallels the degree of inflammation rather than the amount of dietary iron consumed.

Chronic Kidney Disease

Healthy kidneys are endocrine organs as well as filters. Specialized cells within the kidneys continuously monitor oxygen delivery.

When oxygen falls, they release erythropoietin (EPO), the hormone that stimulates red blood cell production.

As chronic kidney disease progresses:

• EPO production declines.
• Bone marrow receives less stimulation.
• Red blood cell production decreases.
• Chronic inflammation may further increase hepcidin.
• Iron utilization becomes less efficient.

Consequently, many women with advanced kidney disease develop a normocytic, normochromic anemia, meaning red blood cells appear relatively normal in size and color but are reduced in number.

Modern treatment often combines:

• Iron replacement (when indicated)
• Erythropoiesis-stimulating agents (ESAs)
• Careful monitoring to avoid excessive hemoglobin correction, which has been associated with increased cardiovascular risk in some clinical trials.

Gastrointestinal Disorders: Hidden Causes of Iron Loss

Not all blood loss is visible. Chronic microscopic bleeding from the gastrointestinal tract may continue for months or years before symptoms become obvious.

This is particularly important in postmenopausal women, in whom gastrointestinal blood loss becomes a leading cause of iron-deficiency anemia.

Common Causes

• Peptic ulcers
• Gastritis
• Colon polyps
• Colorectal cancer
• Gastric cancer
• Angiodysplasia
• Inflammatory bowel disease
• Hemorrhoids (less commonly a sole cause of significant anemia)

For this reason, unexplained iron-deficiency anemia in postmenopausal women frequently prompts evaluation with upper endoscopy and/or colonoscopy, depending on age, symptoms, and clinical risk factors.

Malabsorption Disorders

Sometimes the problem is not blood loss but impaired nutrient absorption.

Celiac Disease

In celiac disease, ingestion of gluten triggers an autoimmune response that damages the small intestine, particularly the duodenum, where most iron absorption occurs.

Iron-deficiency anemia may be the first—and sometimes only—clinical manifestation of celiac disease.

Inflammatory Bowel Disease

Crohn’s disease and ulcerative colitis contribute to anemia through several mechanisms:

• Chronic blood loss
• Reduced iron absorption
• Chronic inflammation
• Vitamin deficiencies
• Medication effects

Multiple mechanisms often coexist, making diagnosis and treatment more complex.

Bariatric Surgery

Procedures such as Roux-en-Y gastric bypass bypass sections of the stomach and small intestine responsible for iron and vitamin B12 absorption.

Without lifelong nutritional monitoring and supplementation, anemia can develop years after surgery.

Inherited Disorders of Red Blood Cells

Although inherited anemias are less common than acquired forms, they are important because their causes, diagnosis, and treatment differ substantially.

Thalassemia

Thalassemia results from inherited mutations that reduce the production of alpha- or beta-globin chains.

Because hemoglobin is produced inefficiently:

• Red blood cells become unusually small (microcytic) and often pale (hypochromic).
• Many developing red blood cells are destroyed in the bone marrow before reaching full maturity (ineffective erythropoiesis), and circulating red blood cells may also be destroyed prematurely.
• Chronic anemia develops.

One important clinical point is that thalassemia trait can resemble iron-deficiency anemia on a complete blood count (CBC). However, unnecessary iron supplementation is ineffective unless iron deficiency is also present.

Diagnosis may include:

• Complete blood count (CBC)
• Hemoglobin electrophoresis (particularly useful for beta-thalassemia; it may be normal in alpha-thalassemia trait)
• Genetic testing, especially when alpha-thalassemia is suspected, or hemoglobin electrophoresis is normal
• Family history

Sickle Cell Disease

Sickle cell disease results from a mutation in the HBB gene, producing abnormal hemoglobin S (HbS).

Under low-oxygen conditions:

• Red blood cells become rigid and sickle-shaped.
• Sickled cells obstruct small blood vessels (vaso-occlusion).
• Oxygen delivery to tissues decreases.
• Premature red blood cell destruction (hemolysis) occurs.

Women with sickle cell disease require specialized care during pregnancy because both maternal and fetal complications occur more frequently than in the general population.

Hereditary Spherocytosis

Hereditary spherocytosis is caused by inherited defects in red blood cell membrane proteins (such as spectrin, ankyrin, band 3, or protein 4.2), producing spherical rather than flexible, biconcave disc-shaped red blood cells.

The spleen rapidly removes these abnormal cells, shortening red blood cell survival from approximately 120 days to only a few weeks in severe cases, resulting in chronic hemolytic anemia.

Medication-Induced Anemia

Certain medications may contribute to anemia through different mechanisms.

Examples include:

Importantly, medications should never be discontinued without medical advice, even when anemia is suspected.

Physical Examination Findings

Clinical examination provides valuable clues regarding both the presence of anemia and its underlying cause. Although no single physical finding is diagnostic, characteristic patterns often guide further investigation.

Common examination findings include:

• Pallor of the conjunctivae, nail beds, palms, and oral mucosa
• Tachycardia
• Flow murmur caused by increased cardiac output
• Orthostatic hypotension in cases of significant blood loss
• Cool extremities
• Spoon-shaped nails (koilonychia) in longstanding iron deficiency
• Smooth, sore tongue (atrophic glossitis)
• Angular cheilitis
• Brittle nails
• Hair thinning

Certain findings suggest specific etiologies:

Iron deficiency

• Koilonychia
• Glossitis

Vitamin B12 deficiency

• Loss of vibration sensation
• Peripheral neuropathy
• Impaired balance
• Cognitive changes

Hemolytic anemia

• Jaundice
• Splenomegaly

Bone marrow disorders

• Petechiae
• Easy bruising
• Enlarged lymph nodes
• Hepatosplenomegaly

Physical examination alone cannot confirm anemia, but it provides essential clinical context for laboratory evaluation.

Laboratory Diagnosis: Looking Beyond Hemoglobin

Diagnosing anemia involves far more than confirming a low hemoglobin level. Physicians use laboratory tests to determine why anemia has developed.

Step 1: Complete Blood Count (CBC)

The CBC provides the foundation for diagnosis.

Key measurements include:

• Hemoglobin (Hb)
• Hematocrit (Hct)
• Red blood cell count (RBC)
• Mean corpuscular volume (MCV)
• Mean corpuscular hemoglobin (MCH)
• Red cell distribution width (RDW)

Among these, MCV helps classify anemia:

This classification guides further investigation but is not diagnostic on its own.

Step 2: Iron Studies

Iron studies help distinguish iron deficiency from other causes.

Because ferritin rises during inflammation, interpretation requires clinical context and, in some cases, inflammatory markers such as C-reactive protein (CRP).

Step 3: Additional Tests

Depending on the suspected cause, clinicians may request:

• Reticulocyte count
• Peripheral blood smear
• Vitamin B12 level
• Folate level
• Kidney function tests
• Liver function tests
• Thyroid function tests
• Lactate dehydrogenase (LDH)
• Bilirubin
• Haptoglobin
• Stool testing for occult blood
• Celiac disease serology
• Hemoglobin electrophoresis
• Bone marrow examination (rarely, when indicated)

Each investigation is selected based on clinical history rather than performed routinely.

Emerging Biomarkers in Modern Anemia Diagnosis

Traditional iron studies remain the cornerstone of diagnosis; however, several newer biomarkers may improve diagnostic accuracy in selected clinical situations.

Soluble Transferrin Receptor (sTfR)

Unlike ferritin, sTfR is minimally affected by inflammation. Elevated levels suggest iron-restricted erythropoiesis and may help distinguish iron-deficiency anemia from anemia of chronic disease.

Reticulocyte Hemoglobin Equivalent (Ret-He)

Ret-He measures the hemoglobin content of newly produced red blood cells, providing an early indication of iron availability for erythropoiesis before hemoglobin declines.

Zinc Protoporphyrin (ZPP)

When iron is unavailable during heme synthesis, zinc is incorporated into protoporphyrin instead. Elevated ZPP may indicate iron-deficient erythropoiesis or lead exposure.

Although promising, these biomarkers are not yet routinely available in all healthcare settings and are generally used alongside conventional laboratory tests rather than replacing them.

A Practical Diagnostic Algorithm

A simplified evidence-based approach includes:

1. Confirm anemia with a complete blood count.
2. Classify anemia by MCV (microcytic, normocytic, or macrocytic).
3. Review the patient’s history, including menstrual patterns, pregnancy, diet, medications, family history, and chronic illnesses.
4. Order targeted laboratory tests, such as ferritin, vitamin B12, folate, kidney function, or inflammatory markers.
5. Investigate the underlying cause, rather than treating low hemoglobin alone.
6. Monitor the response to therapy, adjusting treatment if the expected improvement does not occur.

This systematic process helps avoid common pitfalls, such as assuming every microcytic anemia is caused by iron deficiency.

Differential Diagnosis

Although iron deficiency is the leading cause of anemia, clinicians must distinguish it from numerous other disorders that produce similar laboratory findings.

Important differential diagnoses include:

Accurate diagnosis requires integrating clinical history, laboratory findings, and, when appropriate, imaging or specialized testing.

Clinical Case Study: Connecting the Science to Practice

Case: A 34-year-old woman presents with progressive fatigue, reduced exercise tolerance, and frequent headaches over six months. She reports menstrual periods lasting eight days with heavy bleeding during the first three days.

Initial Findings

• Hemoglobin: 10.1 g/dL
• MCV: 73 fL
• Ferritin: 8 ng/mL
• Transferrin saturation: 9%

These laboratory findings are highly consistent with iron-deficiency anemia.

Rather than prescribing iron alone, her clinician also evaluates the cause of the heavy menstrual bleeding. Pelvic ultrasound identifies multiple uterine fibroids. Treatment therefore addresses both the iron deficiency and the underlying source of chronic blood loss.

Why This Matters

If only the laboratory abnormality had been treated, the anemia would likely have recurred. This example illustrates a central principle of modern hematology:

Successful treatment requires correcting the underlying cause—not simply increasing the hemoglobin level.

Complications of Untreated Anemia

Untreated anemia affects virtually every organ system because oxygen is essential for cellular metabolism.

Potential complications include:

Cardiovascular Complications

Persistent anemia increases cardiac workload as the heart attempts to compensate for reduced oxygen-carrying capacity. Over time, this may result in:

• Left ventricular hypertrophy
• Heart failure
• Angina
• Cardiac arrhythmias

Neurological Effects

Chronic iron deficiency has been associated with:

• Reduced concentration
• Memory impairment
• Decreased cognitive performance
• Restless legs syndrome

Vitamin B12 deficiency may lead to irreversible neurological damage if treatment is delayed.

Pregnancy Complications

Maternal anemia increases the risk of:

• Preterm birth
• Low birth weight
• Maternal fatigue
• Postpartum anemia
• Increased need for blood transfusion
• Perinatal morbidity

Reduced Quality of Life

Women with chronic anemia frequently experience:

• Decreased productivity
• Exercise intolerance
• Reduced work capacity
• Mood disturbances
• Impaired immune function

Early diagnosis and treatment substantially reduce these risks.

Prevention Across the Female Lifespan

Preventing anemia requires addressing its underlying causes before significant reductions in hemoglobin occur.

Childhood and Adolescence

Key preventive strategies include:

• Iron-rich diets
• Early recognition of heavy menstrual bleeding
• Treatment of parasitic infections where endemic
• Nutrition education
• Screening in high-risk populations

Pregnancy

WHO recommends routine iron and folic acid supplementation during pregnancy in many settings because maternal requirements increase substantially.

Regular prenatal care enables:

• Early detection of anemia.
• Monitoring of hemoglobin.
• Timely intervention.

Reproductive Years

Women with heavy menstrual bleeding should receive evaluation rather than repeated short-term iron supplementation alone.

Management may include:

• Hormonal therapies
• Treatment of fibroids
• Treatment of endometriosis
• Surgical interventions when appropriate

Older Women

Following menopause, unexplained iron-deficiency anemia should prompt investigation for gastrointestinal disease, including malignancy when clinically indicated.

Evidence-Based Treatment

Treatment should always target the underlying cause, not simply normalize laboratory values.

Oral Iron

Oral iron remains first-line therapy for uncomplicated iron-deficiency anemia.

Recent research suggests that alternate-day dosing may improve absorption and reduce gastrointestinal side effects for some patients by allowing hepcidin levels to decline between doses.

Common side effects include:

• Nausea
• Constipation
• Diarrhea
• Abdominal discomfort
• Dark stools

Patients should continue therapy long enough to replenish iron stores, not merely normalize hemoglobin.

Intravenous Iron

IV iron is indicated when:

• Oral iron is ineffective.
• Iron absorption is impaired.
• Iron losses are ongoing.
• Rapid correction is required.
• Chronic kidney disease is present.
• Inflammatory bowel disease limits oral therapy.

Modern IV iron formulations have significantly improved safety profiles compared with older preparations.

Blood Transfusion

Blood transfusion is reserved for selected situations such as:

• Severe symptomatic anemia
• Acute hemorrhage
• Hemodynamic instability

Because transfusion carries potential risks—including transfusion reactions, infections (rare with modern screening), circulatory overload, and iron accumulation—it is generally not considered definitive treatment for chronic anemia. Instead, it serves as a temporary measure while the underlying cause is identified and managed.

Iron Overload and Safe Use of Iron Supplements

Although iron deficiency is common, excessive iron can be harmful.

Iron supplements should ideally be taken only after confirmation of deficiency through appropriate clinical evaluation and laboratory testing.

Potential risks of unnecessary supplementation include:

• Constipation
• Nausea
• Abdominal pain
• Iron overdose in children
• Iron overload in individuals with hereditary hemochromatosis or repeated blood transfusions

Iron overload may damage the:

• Liver
• Heart
• Pancreas
• Endocrine glands

Patients should avoid taking higher-than-recommended doses unless directed by a healthcare professional.

Nutrition: Beyond Iron Alone

Nutrition plays a central role in maintaining healthy blood formation, but iron is only one component of the process. The production of red blood cells depends on a balanced intake of multiple nutrients, including iron, vitamin B12, folate, vitamin B6, copper, and adequate dietary protein. While correcting iron deficiency is often a primary goal, a varied and nutrient-rich diet supports normal erythropoiesis and helps reduce the risk of nutritional anemia.

Iron occurs in two dietary forms—heme iron and non-heme iron—which differ in their food sources and absorption efficiency. Understanding these differences can help individuals make informed dietary choices, particularly those at increased risk of iron deficiency.

Foods Rich in Heme Iron

Heme iron is found exclusively in animal-derived foods and is the most efficiently absorbed form of dietary iron. Because it is less affected by other dietary components, heme iron generally contributes more effectively to maintaining healthy iron stores.

Good sources of heme iron include:

• Lean beef
• Lamb
• Poultry
• Fish
• Shellfish
• Liver (consumed in moderation, particularly during pregnancy because of its high vitamin A content)

Including moderate amounts of these foods as part of a balanced diet can help support healthy hemoglobin production, especially for individuals with increased iron requirements.

Foods Rich in Non-Heme Iron

Non-heme iron is present in plant-based foods and fortified products. Although it provides an important source of dietary iron, its absorption is generally lower than that of heme iron and is influenced by other components of the diet.

Nutritious sources of non-heme iron include:

• Lentils
• Chickpeas
• Beans
• Soy products
• Spinach
• Pumpkin seeds
• Quinoa
• Iron-fortified breakfast cereals

Plant-based diets can provide sufficient iron when they are carefully planned and include a variety of iron-rich foods. Women who follow vegetarian or vegan diets may benefit from paying particular attention to iron intake and combining iron-rich foods with nutrients that enhance absorption.

Vitamin C and Iron Absorption

Vitamin C plays an important role in improving the absorption of non-heme iron by converting it into a form that is more readily absorbed in the small intestine. Pairing plant-based iron sources with vitamin C-rich foods can significantly increase iron availability.

Examples of foods rich in vitamin C include:

• Citrus fruits
• Guava
• Kiwi
• Strawberries
• Bell peppers
• Tomatoes

Some dietary components can reduce non-heme iron absorption. Tea and coffee contain polyphenols, while phytates found in some whole grains and legumes may also inhibit absorption. For individuals at increased risk of iron deficiency, consuming tea or coffee between meals rather than alongside iron-rich meals may help maximize iron absorption.

Although nutrition is an important component of anemia prevention and management, dietary changes alone may not correct moderate or severe anemia. When anemia is present, medical evaluation is essential to determine the underlying cause and identify the most appropriate treatment strategy.

Special Populations

Vegetarians and Vegans

Vegetarian and vegan diets can support good health but require careful nutritional planning.

Plant foods contain only non-heme iron, which is absorbed less efficiently than heme iron from animal products. Additionally, phytates found in legumes and whole grains may reduce iron absorption.

Women following vegetarian or vegan diets should:

• Consume iron-rich legumes, beans, lentils, tofu, quinoa, pumpkin seeds, and fortified cereals.
• Pair iron-rich foods with vitamin C-rich fruits and vegetables.
• Monitor vitamin B12 status, as deficiency is common without supplementation.
• Consider periodic iron assessment if additional risk factors such as heavy menstrual bleeding are present.

When appropriately planned, vegetarian diets do not inevitably lead to anemia.

Female Athletes

Female athletes have unique risk factors for iron deficiency due to the combined effects of:

• Increased iron losses through menstruation
• Repetitive foot-strike hemolysis in runners
• Sweat-related iron loss
• Increased erythropoiesis
• High training volume
• Inadequate energy intake

Iron deficiency—even without anemia—may impair endurance, aerobic capacity, and athletic performance. Sports medicine guidelines recommend targeted screening for athletes with fatigue, declining performance, or multiple risk factors.

Scientific Debates and Unanswered Questions

Even with remarkable advances, important controversies remain.

Should Everyone Be Screened?

Routine screening recommendations vary among professional organizations.

High-risk groups clearly benefit from targeted screening, including:

• Pregnant women
• Individuals with heavy menstrual bleeding
• Chronic kidney disease
• Inflammatory bowel disease

Whether universal adult screening provides additional benefit remains uncertain.

Ferritin Cut-Off Values

Ferritin is the best indicator of iron stores under most circumstances.

However:

• Inflammation raises ferritin.
• Obesity raises ferritin.
• Liver disease raises ferritin.

Researchers continue investigating more accurate diagnostic thresholds for different clinical populations.

Oral Versus Intravenous Iron

Both treatments are effective when appropriately selected.

Current evidence suggests:

• Oral iron is appropriate for many uncomplicated cases.
• IV iron provides faster correction and is preferred when absorption is impaired, inflammation limits oral efficacy, or rapid replacement is needed.

Choice should be individualized based on the patient’s clinical situation rather than a one-size-fits-all approach.

A Brief History of Scientific Discovery

The modern understanding of anemia emerged gradually through centuries of medical observation and scientific discovery.

• 1628: William Harvey described the circulation of blood, establishing the foundation of cardiovascular physiology.
• Mid-19th century: Improvements in microscopy enabled scientists to identify and study red blood cells.
• 1926: George Minot and William Murphy demonstrated that liver therapy could treat pernicious anemia, a discovery that later earned the Nobel Prize.
• 1940s–1960s: Researchers elucidated the roles of iron, vitamin B12, and folate in red blood cell production.
• Early 2000s: The identification of hepcidin revolutionized understanding of iron regulation, revealing why chronic inflammation can cause anemia even in the presence of adequate iron stores.

This evolving knowledge has shifted the clinical approach from primarily treating low hemoglobin or replacing iron when appropriate to identifying the underlying cause and biological mechanisms responsible for anemia, enabling more targeted therapy.

Current Research and Recent Scientific Advances

The last decade has transformed the scientific understanding of anemia. While iron deficiency remains the leading cause globally, researchers now recognize that iron metabolism is governed by a sophisticated network of hormones, immune signals, genetic regulators, and environmental influences. Advances in molecular biology, precision medicine, and computational diagnostics are reshaping how clinicians diagnose and treat anemia.

Rather than asking only “Does this patient need more iron?”, physicians increasingly ask “Why is the body unable to produce healthy red blood cells or use the iron it already has?”

Hepcidin: From Discovery to Clinical Application

One of the most important developments in hematology has been the growing clinical importance of hepcidin.

Although discovered in the early 2000s, research published over the past five years has clarified its central role in iron homeostasis.

Investigators are evaluating whether measuring circulating hepcidin concentrations could help physicians:

• Distinguish iron-deficiency anemia from anemia of inflammation.
• Predict response to oral iron therapy.
• Identify patients who may benefit from intravenous iron.
• Monitor recovery during treatment.

Current Evidence

Early clinical studies are promising, but important challenges remain.

• Different laboratories use different testing methods.
• Standard reference ranges have not been universally established.
• Hepcidin levels fluctuate with infection, inflammation, and time of day.

Scientific confidence: Moderate.

Most professional societies do not currently recommend routine hepcidin testing outside research settings, although this may change as standardized assays become available.

Precision Medicine: Treating the Individual Rather Than the Disease

Historically, anemia was classified primarily by red blood cell size.

Modern genomics is shifting this approach toward precision medicine, where treatment is tailored according to the patient’s unique biological mechanisms.

Researchers are identifying genetic variants affecting:

• Iron absorption
• Iron transport
• Iron storage
• Hemoglobin synthesis
• Bone marrow function
• Red blood cell survival

This approach is especially valuable for patients with inherited disorders such as thalassemia, sickle cell disease, hereditary hemochromatosis, and rare congenital anemias.

Although precision medicine remains an emerging field, it illustrates the broader trend toward individualized hematology.

Artificial Intelligence in Hematology

Artificial intelligence (AI) is increasingly being integrated into laboratory medicine.

Researchers have developed machine-learning systems capable of analyzing:

• Digital blood smear images
• Complete blood count patterns
• Iron study results
• Electronic health records

Potential applications include:

• Earlier detection of iron deficiency.
• Automated recognition of abnormal red blood cell morphology.
• Identification of inherited blood disorders.
• Clinical decision support for physicians.

Current Limitations

Despite encouraging results, AI systems face important challenges:

• Limited validation across diverse populations.
• Potential algorithmic bias.
• Dependence on high-quality laboratory data.
• Need for physician oversight.

Scientific consensus remains clear: AI should augment clinical expertise, not replace it.

Emerging Therapies

Several novel therapeutic approaches are currently under investigation.

Hepcidin-Targeted Drugs

Researchers are developing medications designed to:

• Lower excessive hepcidin levels.
• Improve iron availability.
• Treat anemia associated with chronic inflammation.

These therapies remain experimental and are not yet standard clinical practice.

Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PH) Inhibitors

A newer class of medications stimulates the body’s natural response to low oxygen.

These drugs increase endogenous erythropoietin production while improving iron utilization.

Several HIF-PH inhibitors have been approved in some regions for selected patients with anemia associated with chronic kidney disease. Their long-term safety continues to be evaluated.

Scientific Consensus vs. Emerging Research

Current evidence strongly supports the following conclusions:

Established Scientific Consensus

• Iron deficiency is the most common cause of anemia worldwide.
• Heavy menstrual bleeding is a leading cause of iron deficiency in women of reproductive age.
• Pregnancy substantially increases iron requirements.
• Hepcidin is the central regulator of systemic iron metabolism.
• Treating anemia requires identifying and addressing the underlying cause.

Emerging Areas of Research

• Routine clinical use of hepcidin testing to guide therapy.
• AI-assisted diagnosis using digital blood smear analysis.
• Precision medicine approaches based on genetic variation in iron metabolism.
• Novel therapies that target the hepcidin–ferroportin pathway.

These developments are promising but require further validation before becoming standard clinical practice.

Future Outlook

Several developments are likely to shape anemia care over the next decade:

• Standardized hepcidin assays for clinical use.
• AI-assisted interpretation of laboratory data.
• Improved biomarkers that detect iron deficiency before anemia develops.
• Expanded use of genomic testing for inherited disorders.
• Novel therapies targeting iron regulation pathways.
• Greater emphasis on personalized medicine.
• Public health initiatives focused on adolescent girls and maternal nutrition.

Although these advances are promising, the greatest gains are still likely to come from ensuring timely diagnosis, equitable access to healthcare, and effective management of common causes such as iron deficiency and heavy menstrual bleeding.

Public Health and Global Impact

Anemia affects not only individual health but also societies.

Its consequences include:

• Reduced educational achievement
• Decreased workplace productivity
• Increased maternal morbidity
• Greater healthcare costs
• Reduced quality of life

Public health strategies that have demonstrated benefit include:

• Iron fortification of staple foods
• Prenatal supplementation programs
• Malaria control in endemic regions
• Deworming where parasitic infections are common
• Improved access to reproductive healthcare
• Education regarding menstrual health and nutrition

Reducing anemia therefore requires coordinated efforts across healthcare, nutrition, education, and public policy.

Key Takeaways

• Anemia is a clinical sign, not a disease. Identifying the underlying cause is essential.
• Iron deficiency remains the leading cause globally, but chronic inflammation, kidney disease, vitamin deficiencies, inherited disorders, and blood loss also contribute substantially.
• Women face unique physiological risks because of menstruation, pregnancy, childbirth, and certain gynecological conditions.
• Hepcidin is the master regulator of iron metabolism, explaining why inflammation can impair iron utilization even when body iron stores appear adequate.
• Diagnosis requires more than measuring hemoglobin. Complete blood count, iron studies, vitamin levels, and clinical history are all important.
• Treatment should address the underlying mechanism, not merely increase hemoglobin levels.
• Emerging research in precision medicine, hepcidin biology, and AI has the potential to improve future diagnosis and treatment.

Red Flags Requiring Urgent Medical Evaluation

Although many cases of anemia develop gradually, certain symptoms and clinical findings require prompt medical assessment.

Seek urgent medical evaluation if anemia is accompanied by:

• Chest pain
• Severe shortness of breath at rest
• Fainting or recurrent syncope
• Rapid or irregular heartbeat
• Black, tarry stools or visible gastrointestinal bleeding
• Vomiting blood
• Heavy menstrual bleeding causing dizziness or hemodynamic instability
• Sudden onset of severe weakness
• Confusion or altered mental status
• Hemoglobin levels consistent with severe anemia or rapidly falling values

These findings may indicate acute blood loss, cardiovascular compromise, gastrointestinal hemorrhage, or another serious underlying condition requiring immediate treatment.

Frequently Asked Questions

Is iron deficiency the same as anemia?

No. Iron deficiency refers to depleted iron stores. Anemia occurs when iron deficiency—or another cause—reduces hemoglobin below normal levels. Iron deficiency can exist without anemia.

Why are women more likely than men to develop anemia?

Regular menstrual blood loss, pregnancy, childbirth, and certain gynecological conditions increase iron requirements and blood loss, making women more susceptible throughout much of their lives.

Can anemia occur even when iron intake is adequate?

Yes. Chronic inflammation, kidney disease, inherited blood disorders, vitamin deficiencies, and impaired nutrient absorption can all cause anemia despite adequate dietary iron.

Are iron supplements safe?

Iron supplements are generally safe when prescribed appropriately, but unnecessary supplementation may cause gastrointestinal side effects and, in rare circumstances, iron overload in susceptible individuals. Supplementation should ideally be guided by clinical evaluation and laboratory testing.

Can diet alone correct anemia?

Some mild cases of iron deficiency respond to dietary improvement, but many patients require iron supplementation or treatment of the underlying cause. Diet alone is often insufficient for moderate or severe anemia.

When should someone seek medical evaluation?

Persistent fatigue, unexplained weakness, shortness of breath, heavy menstrual bleeding, recurrent dizziness, black or bloody stools, or symptoms that interfere with daily life warrant medical assessment. Self-treating presumed anemia without evaluation can delay diagnosis of serious underlying conditions.

Myths vs. Facts About Anemia

Conclusion

Anemia in women is far more than a simple nutritional problem. It reflects the intricate interplay of iron metabolism, hormonal physiology, genetics, immune regulation, chronic disease, and environmental influences. Modern hematology has shown that successful management depends not merely on replacing iron but on understanding why oxygen delivery has become impaired in the first place.

From adolescence through pregnancy, menopause, and older age, the causes of anemia evolve alongside the biological demands placed on the female body. Heavy menstrual bleeding, pregnancy, chronic inflammatory disorders, gastrointestinal disease, inherited hemoglobin disorders, and kidney disease each require distinct diagnostic approaches and individualized treatment strategies.

Scientific advances—from the discovery of hepcidin to the emergence of precision medicine and artificial intelligence—are transforming anemia care. Yet the most powerful tools remain early recognition, evidence-based diagnosis, equitable access to healthcare, and interventions that address root causes rather than symptoms alone.

Ultimately, anemia should be viewed not simply as a laboratory abnormality but as a vital biological signal—one that offers clinicians an opportunity to uncover treatable conditions, improve long-term health, and reduce one of the world’s most persistent public health challenges.

References

• Auerbach, M., & Adamson, J. W. (2015). How we diagnose and treat iron deficiency anemia. American Journal of Hematology, 91(1), 31–38. https://doi.org/10.1002/ajh.24201
• American Society of Hematology. (2023). Iron-deficiency anemia. https://www.hematology.org/education/patients/anemia/iron-deficiency
• Bolton-Maggs, P. H. B., Langer, J. C., Iolascon, A., Tittensor, P., & King, M. J. (2011). Guidelines for the diagnosis and management of hereditary spherocytosis. British Journal of Haematology, 156(1), 37–49. https://doi.org/10.1111/j.1365-2141.2011.08921.x
• Camaschella, C. (2015). Iron-deficiency anemia. The New England Journal of Medicine, 372(19), 1832–1843. https://doi.org/10.1056/NEJMra1401038
• Cappellini, M. D., Musallam, K. M., & Taher, A. T. (2019). Iron deficiency anaemia revisited. Journal of Internal Medicine, 287(2), 153–170. https://doi.org/10.1111/joim.13004
• Chen, I., Khamisa, K., Murji, A., Coolen, J., Evans, D., Lett, R., Rittenberg, D., & Lett, C. (2026). No. 469: Iron deficiency and iron deficiency anemia in obstetrics and gynaecology. Journal of Obstetrics and Gynaecology Canada. Advance online publication. https://doi.org/10.1016/j.jogc.2026.103428
• DeLoughery, T. G., Jackson, C. S., Ko, C. W., & Rockey, D. C. (2024). AGA clinical practice update on management of iron deficiency anemia: Expert review. Clinical Gastroenterology and Hepatology, 22(8), 1575–1583. https://doi.org/10.1016/j.cgh.2024.03.046
• DeLoughery, T. G. (2014). Microcytic anemia. The New England Journal of Medicine, 371(14), 1324–1331. https://doi.org/10.1056/NEJMra1215361
• Enns, C. A., & Zhang, A. S. (2013). Iron regulation by hepcidin. Journal of Clinical Investigation, 123(6), 2337–2343. https://doi.org/10.1172/JCI67225
• Fletcher, A., Forbes, A., Svenson, N., & Thomas, D. W. (2021). Guideline for the laboratory diagnosis of iron deficiency in adults (excluding pregnancy) and children: A British Society for Haematology good practice paper. British Journal of Haematology, 196(3), 523–529. https://doi.org/10.1111/bjh.17900
• Ganz, T. (2013). Systemic iron homeostasis. Physiological Reviews, 93(4), 1721–1741. https://doi.org/10.1152/physrev.00008.2013
• Ganz, T., & Nemeth, E. (2012). Hepcidin and iron homeostasis. Biochimica et Biophysica Acta, 1823(9), 1434–1443. https://doi.org/10.1016/j.bbamcr.2012.01.014
• Ganz, T., & Nemeth, E. (2015). Iron homeostasis in host defence and inflammation. Nature Reviews Immunology, 15(8), 500–510. https://doi.org/10.1038/nri3863
• Ganz, T. (2019). Anemia of inflammation. The New England Journal of Medicine, 381(12), 1148–1157. https://doi.org/10.1056/NEJMra1804281
• Kaushansky, K., Lichtman, M. A., Prchal, J. T., Levi, M. M., Press, O. W., & Burns, L. J. (2021). Williams hematology (10th ed.). McGraw Hill. https://accessmedicine.mhmedical.com/book.aspx?bookID=2962
• Kidney Disease: Improving Global Outcomes (KDIGO). (2026). KDIGO clinical practice guideline for the management of anemia in chronic kidney disease (CKD). Kidney International, 109(1S), S1–S99. https://doi.org/10.1016/j.kint.2025.06.006
• Loscalzo, J., Fauci, A. S., Kasper, D. L., Hauser, S. L., Longo, D. L., & Jameson, J. L. (Eds.). (2022). Harrison’s principles of internal medicine (21st ed.). McGraw Hill. https://accessmedicine.mhmedical.com/book.aspx?bookID=3095
• McLean, E., Cogswell, M., Egli, I., Wojdyla, D., & de Benoist, B. (2009). Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005. Public Health Nutrition, 12(4), 444–454. https://doi.org/10.1017/S1368980008002401
• Mast, A. E., Blinder, M. A., Gronowski, A. M., Chumley, C., & Scott, M. G. (1998). Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clinical Chemistry, 44(1), 45–51. https://doi.org/10.1093/clinchem/44.1.45
• Means, R. T., Jr. (2022). Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia. Hematology/Oncology Clinics of North America, 36(2), 247–258. https://doi.org/10.1016/j.hoc.2021.11.001
• Mansour, D., Hofmann, A., & Gemzell-Danielsson, K. (2020). A review of clinical guidelines on the management of iron deficiency and iron-deficiency anemia in women with heavy menstrual bleeding. Advances in Therapy, 38(1), 201–225. https://doi.org/10.1007/s12325-020-01564-y
• National Institutes of Health, Office of Dietary Supplements. (2024). Iron: Fact sheet for health professionals. https://ods.od.nih.gov/factsheets/Iron-HealthProfessional/
• National Institutes of Health, Office of Dietary Supplements. (2024). Vitamin B12: Fact sheet for health professionals. https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/
• National Institutes of Health, Office of Dietary Supplements. (2024). Folate: Fact sheet for health professionals. https://ods.od.nih.gov/factsheets/Folate-HealthProfessional/
• National Institutes of Health, Office of Dietary Supplements. (2024). Vitamin B6: Fact sheet for health professionals. https://ods.od.nih.gov/factsheets/VitaminB6-HealthProfessional/
• Pavord, S., Daru, J., Prasannan, N., Robinson, S., Stanworth, S., & Girling, J. (2019). UK guidelines on the management of iron deficiency in pregnancy. British Journal of Haematology, 188(6), 819–830. https://doi.org/10.1111/bjh.16221
• Peña-Rosas, J. P., De-Regil, L. M., Garcia-Casal, M. N., & Dowswell, T. (2015). Daily oral iron supplementation during pregnancy. Cochrane Database of Systematic Reviews, 2015(7), CD004736. https://doi.org/10.1002/14651858.CD004736.pub5
• Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010). Sickle-cell disease. The Lancet, 376(9757), 2018–2031. https://doi.org/10.1016/S0140-6736(10)61029-X
• Short, M. W., & Domagalski, J. E. (2013). Iron deficiency anemia: Evaluation and management. American Family Physician, 87(2), 98–104. https://www.aafp.org/pubs/afp/issues/2013/0115/p98.html
• Tefferi, A. (2003). Anemia in adults: A contemporary approach to diagnosis. Mayo Clinic Proceedings, 78(10), 1274–1280. https://doi.org/10.4065/78.10.1274
• Weiss, G., & Goodnough, L. T. (2005). Anemia of chronic disease. The New England Journal of Medicine, 352(10), 1011–1023. https://doi.org/10.1056/NEJMra041809
• World Health Organization. (2020). WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations. World Health Organization. https://www.who.int/publications/i/item/9789240000124
• World Health Organization. (2025). Anaemia. https://www.who.int/news-room/fact-sheets/detail/anaemia
• Weatherall, D. J., & Clegg, J. B. (2001). The thalassaemia syndromes (4th ed.). Blackwell Science. https://doi.org/10.1002/9780470696705
• World Health Organization. (2012). Guideline: Daily iron and folic acid supplementation in pregnant women. World Health Organization. https://apps.who.int/iris/handle/10665/77770
• World Health Organization. (2016). WHO recommendations on antenatal care for a positive pregnancy experience. World Health Organization. https://apps.who.int/iris/handle/10665/250796

Disclaimer

This article is intended solely for educational and informational purposes and should not be interpreted as medical advice, diagnosis, or treatment. Every effort has been made to ensure that the information presented is accurate, evidence-based, and consistent with current scientific literature and clinical guidelines available at the time of writing. However, medical knowledge and clinical recommendations continue to evolve, and newer evidence may emerge after publication.

The content is designed to provide a comprehensive scientific overview of anemia in women and should not replace consultation with a qualified healthcare professional. Readers should not use this article to diagnose or treat any medical condition or to make decisions regarding medications, dietary supplements, or medical care without appropriate professional guidance.

Individuals experiencing symptoms such as persistent fatigue, unexplained weakness, shortness of breath, dizziness, heavy menstrual bleeding, chest pain, fainting, or signs of gastrointestinal bleeding should seek prompt medical evaluation. Appropriate diagnosis and treatment require consideration of an individual’s medical history, physical examination, laboratory findings, and other clinical factors.

References to medications, laboratory tests, nutritional supplements, clinical guidelines, and emerging research are provided for educational purposes only and should not be interpreted as endorsements or recommendations for self-treatment. Discussions of investigational therapies and developing areas of research reflect the current state of scientific knowledge and may not represent established standards of clinical practice.

For personalized medical advice, diagnosis, or treatment, readers should consult a licensed physician or another qualified healthcare professional.

You may also like to read….

What Causes Pigmentation in Females? A Complete Scientific Guide to the Biology, Causes, Hormonal Influences, Prevention, and Treatment of Skin Pigmentation (2026) – Women’s Wellness Hub

What Causes Pimples in Females? The Complete Science Behind Acne, Hormones, and Skin Biology (2026) – Women’s Wellness Hub

How To Fix Postpartum Depression? (2026) – Women’s Wellness Hub

What Is the Best Treatment for Menopause? A Scientific Review of Modern Therapies, Hormone Replacement, and Emerging Research (2026) – Women’s Wellness Hub

What Is the Reason for Having PCOD? The Science Behind One of the World’s Most Common Hormonal Disorders (2026) – Women’s Wellness Hub